IQVIA Holdings, IncNYSE: IQV
Health Care · Life Sciences Tools & Services
$168.20
-1.45%
Vol: 2.2M
Research Digest
Friday, June 19, 2026
Morgan Stanley downgrades IQVIA to Equal Weight on AI disruption risk despite record $34.2B backlog and Nvidia AI platform launch
Morgan Stanley downgraded IQVIA Holdings to Equal Weight with a price target of $200, citing long-term uncertainty from AI-driven pharma insourcing and structural changes in clinical research outsourcing. This comes despite strong Q1 2026 results where IQVIA reported adjusted EPS of $2.90 and revenue of $4.15 billion, with backlog reaching a record $34.2 billion of which $8.9 billion is expected to convert to revenue in the next 12 months. IQVIA launched its IQVIA.ai Unified Agentic AI Platform in collaboration with Nvidia, with 192 specialized AI agents deployed across 64 use cases at 19 of the top 20 pharma companies. In June, IQVIA's subsidiary priced €950 million in senior notes due 2033 to refinance existing debt, while the company raised its full-year 2026 revenue guidance to $17.15-$17.35 billion. The Morgan Stanley downgrade introduces near-term selling pressure despite strong operational fundamentals.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21IQVIA beat Q1 with $2.90 EPS, raised full-year guidance and expanded Kexing Biopharm AI biosimilars dealPositive▶
IQVIA on May 5, 2026 reported Q1 EPS of $2.90 beating estimates by $0.05 with revenue of $4.151B, prompting raised 2026 guidance to revenue of $17.15B-$17.35B and adjusted EPS of $12.65-$12.95. Commercial Solutions revenue climbed 11.6% YoY to $1.754B and R&D Solutions grew 6.2%. The company on May 14 expanded its collaboration with Kexing Biopharm to support a multi-product biosimilar program incorporating IQVIA's AI capabilities. The board also authorized an additional $2B in stock buybacks bringing total to $3.2B. Risk: shares are down 23.3% YTD as investors worry AI will compress economics faster than it drives demand.
May 20IQVIA expanded Kexing Biopharm AI biosimilars deal May 14 and authorized additional $2B buyback after Q1 beat.Positive▶
IQVIA on May 14, 2026 announced an expansion of its strategic collaboration with Kexing Biopharm, integrating IQVIA's AI capabilities to support a multi-product biosimilar program across clinical development, regulatory strategy, analytics, and commercialization for international markets. Q1 2026 results (May 5) beat with EPS of $2.90 vs $2.85 estimate and revenue of $4.15B (up 8.4% YoY), with Commercial Solutions revenue climbing 11.6% to $1,754M and R&D Solutions up 6.2% to $2,397M. Adjusted EBITDA rose 5.5% to $932M (22.5% margin). FY26 guidance was raised: revenue $17.15B-$17.35B, adjusted EBITDA $3.975B-$4.025B, adjusted EPS $12.65-$12.95. The board authorized an additional $2B buyback, taking remaining authorization to $3.2B. Stock dropped 4.9% post-earnings to $152.98, but 16 analysts maintain a "Strong Buy" with a $227.13 average target.
May 19IQVIA expands AI-driven biosimilars collaboration with Kexing Biopharm on May 14 following Q1 beat and $2B buyback authorizationPositive▶
On May 14, 2026, IQVIA announced an expansion of its collaboration with Kexing Biopharm, aligning clinical development, regulatory strategy, analytics, and commercialization to support Kexing's multi-product biosimilar program for international markets using IQVIA's AI capabilities for faster trials. Q1 2026 results (May 5) delivered revenue of $4.15B (up 8.4% YoY) and adjusted diluted EPS of $2.90, beating estimates; Commercial Solutions grew 11.6% YoY and R&D Solutions grew 6.2%. The board authorized an additional $2 billion in share buybacks, bringing remaining authorization to $3.2B. Management raised FY2026 adjusted diluted EPS guidance to a $12.65-$12.95 range. Consensus among 16 analysts is Strong Buy with an average 12-month price target of $227.13. Risk: R&D Solutions growth is markedly slower than Commercial Solutions, and adjusted EBITDA margin contraction warrants monitoring.
May 18IQVIA expands Kexing Biopharm AI biosimilars collaboration on May 14, 2026, after a $2B buyback authorization and Q1 beat that raised FY26 EPS guide to $12.65-$12.95.Positive▶
IQVIA announced on May 14, 2026 an expansion of its collaboration with Kexing Biopharm, aligning clinical development, regulatory strategy, analytics and commercialization for Kexing's multi-product biosimilar program and embedding IQVIA's AI capabilities for faster trials. The deal follows a strong Q1 2026 print on May 5 where adjusted EPS of $2.90 beat the $2.85 estimate and revenue of $4.151B beat by ~$10M, prompting management to raise FY26 guidance to revenue of $17.15B-$17.35B, adjusted EBITDA of $3.975B-$4.025B and adjusted diluted EPS of $12.65-$12.95. Commercial Solutions grew 11.6% YoY to $1.754B, outpacing R&D Solutions at 6.2% growth to $2.397B. Q1 free cash flow was $491M, up 15% from $426M a year ago. On May 7, IQVIA expanded its share repurchase authorization by an additional $2 billion.
May 15IQVIA up 12.8% after Q1 2026 beat, raised guidance and $2B incremental buyback authorizationPositive▶
IQVIA reported Q1 2026 EPS of $2.90, beating $2.85 consensus, on record revenue of $4.151B (+~6% YoY) on May 5, 2026. The company raised full-year 2026 guidance to $17.15B-$17.35B revenue, adjusted EBITDA of $3.975B-$4.025B and adjusted EPS of $12.65-$12.95. The board authorized an additional $2.0B share repurchase, bringing total available authorization to $3.2B and lifetime program to $15.73B. Commercial Solutions revenue rose 11.6% YoY to $1.754B with Research & Development Solutions up 6.2% to $2.397B. Free cash flow was $491M, up 15%. Shares are up 12.8% post-earnings. Consensus rating is Strong Buy across 16 analysts with 12-month price target of $227.13 implying about 27% upside.
May 14IQVIA up 12.8% after Q1 2026 beat with $4.15B revenue and $2B share repurchase authorization expansionPositive▶
IQVIA reported Q1 2026 revenue of $4.151B and adjusted EPS of $2.90, beating expectations on May 5, with Commercial Solutions revenue up 11.6% YoY to $1.75B. The company raised full-year 2026 guidance to revenue of $17.15-$17.35B and adjusted EPS of $12.65-$12.95. On May 7, the board authorized an additional $2B share repurchase, bringing total remaining authorization to $3.2B. Free cash flow was $491M, up 15% YoY. CFO Mike Fedock presented at Bank of America Healthcare Conference on May 13. The company is also expanding its AI biosimilar collaboration with Kexing Biopharm.
May 13IQVIA shares jumped 12.8% after Q1 2026 beat (EPS $2.90), raised FY guidance, and $2.0B buyback authorization boost.Positive▶
IQVIA reported Q1 2026 revenue of $4.151B and adjusted EPS of $2.90, beating Wall Street expectations on May 5. Commercial Solutions grew 11.6% YoY to $1.754B (8.5% constant currency) outpacing R&D Solutions at 6.2% growth. The company raised full-year guidance to revenue of $17.15-17.35B, adjusted EBITDA of $3.975-4.025B and adjusted EPS of $12.65-12.95. Share buyback authorization expanded by $2.0B to a total $15.73B program. CFO Mike Fedock presented at the BofA Health Care Conference May 13. Stock up 12.8% post-beat. Risk: $34.2B backlog with concerns over slower organic growth and longer trial durations.
May 12IQVIA Holdings jumped 12.8% after Q1 2026 beat and Board authorized an additional $2 billion share repurchase on May 7, 2026.Positive▶
IQVIA reported Q1 2026 results on May 5, with revenue up 8.4% YoY to $4.15 billion (beating $4.14B estimate) and EPS of $2.90 (beating $2.85 estimate). Net income was $274 million. The company reaffirmed full-year 2026 revenue guidance of $17.15B-$17.35B. On May 7, the Board authorized an additional $2 billion share repurchase, bringing total remaining authorization to $3.2 billion. The stock rose 12.8% following the beat and expanded buyback. CFO Mike Fedock presented at the Bank of America Health Care Conference in Las Vegas on May 13. According to 16 analysts, the average rating for IQV is Strong Buy with a 12-month price target of $227.13, representing 27.09% upside.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $466.53 | +1.05% | +3.4% | 19.2x | 0.87 | $194.5B |
| DHRDANAHER | $177.74 | -0.01% | +2.7% | 21.5x | 0.82 | $140.1B |
| WATWATERS | $356.50 | -0.14% | +2.8% | 23.0x | 1.20 | $37.2B |
| AAGILENT | $127.36 | +2.44% | -1.6% | 19.8x | 1.25 | $36.9B |
| IQVIQVIA | $168.20 | -1.45% | +7.1% | 14.6x | 1.20 | $34.6B |
| MTDMETTLER | $1,150.03 | +1.81% | +3.9% | 25.5x | 1.25 | $26.4B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.